Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights GlobeNewswire - Wed Nov 6, 3:01PM CST

DNLI : 28.45 (-3.98%)
Healthcare (names A - H) - Bio-Techne Corp logo and data-by Piotr Swat via Shutterstock
Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector? Barchart - Wed Sep 25, 9:33AM CDT

Bio-Techne has underperformed the healthcare sector over the past year, yet analysts remain strongly bullish about the stock’s prospects.

TECH : 72.54 (-4.46%)
XLV : 144.52 (-1.57%)
DNLI : 28.45 (-3.98%)
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 28.45 (-3.98%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics PR Newswire - Mon Oct 2, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 28.45 (-3.98%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List PR Newswire - Wed Sep 27, 2023

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 28.45 (-3.98%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR Newswire - Mon Sep 11, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 28.45 (-3.98%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner PR Newswire - Tue Aug 29, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 28.45 (-3.98%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 28.45 (-3.98%)
FHTX : 8.80 (-0.56%)
MRNA : 39.77 (-5.62%)
OMGA : 1.0100 (-5.61%)
SANA : 2.59 (-2.63%)
MCRB : 0.5921 (+0.32%)
Author
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential MarketBeat - Thu May 18, 2023

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 28.45 (-3.98%)
RARE : 47.64 (-2.20%)
SRPT : 109.11 (-3.00%)
PFE : 26.02 (-2.62%)
EXEL : 35.05 (-0.40%)
MRNA : 39.77 (-5.62%)
UTHR : 386.27 (-3.54%)
BIIB : 164.89 (-0.54%)
SNY : 47.82 (-3.41%)
LLY : 786.23 (-3.15%)
Why Shares of Denali Therapeutics Are Up Monday Motley Fool - Mon May 15, 2023

Analysts maintained their buy ratings on the clinical-stage biotech company.

DNLI : 28.45 (-3.98%)

Barchart Exclusives

2 Energy Dividend Stocks to Buy This November for Growth and Income Barchart - Thu Nov 14, 6:30PM CST
For investors seeking steady gains, these two dividend-paying energy stocks could be smart picks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot